Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making

L Andronis, P Barton and S Bryan*

Department of Health Economics, University of Birmingham, UK

*Corresponding author. Present address: Centre for Clinical Epidemiology & Evaluation, University of British Columbia, Vancouver, BC, Canada

Executive summary

Health Technology Assessment 2009; Vol. 13: No. 29
DOI: 10.3310/hta13290
Executive summary: Sensitivity analysis in economic evaluation

Introduction

Economic analyses are increasingly being used to inform technology adoption and reimbursement decisions in health care in the UK and in other countries. The growing influence of economic analyses within reimbursement agencies such as the National Institute for Health and Clinical Excellence (NICE) emphasises the importance of methodological rigour in cost-effectiveness work.

The starting point for this work was that the appropriate characterisation of uncertainty is an essential component in an economic analysis of a health technology. However, it is unclear whether good practice is being adopted in such analyses, and the influence of sensitivity analysis, and probabilistic sensitivity analysis (PSA) in particular, on NICE decision-making is unknown.

Research questions

• How do we define good practice in sensitivity analysis in general and PSA in particular? (Phase 1)
• To what extent has good practice been adhered to in the independent economic evaluations undertaken for NICE over recent years? (Phase 2)
• What policy impact does sensitivity analysis have in the context of NICE? (Phase 3)
• What views do policy-makers have on sensitivity analysis and uncertainty, and what use is made of sensitivity analysis in policy decision-making? (Phase 4)

Phase 1: Literature review

Using a review of the literature, the meaning of ‘good practice’ in the broad area of sensitivity analysis was explored. The literature review revealed that all forms of sensitivity analysis, notably both deterministic and probabilistic approaches, have their supporters and their detractors. The review has summarised arguments for and against alternative approaches, with an outline of good practice (see Recommendations for practice and policy) for each form of analysis.

• Deterministic sensitivity analysis: explanation for the source of ranges used should be provided, along with justification for choice of variables included.
• Analysis of extremes: clear presentation of analysis is required to allow generalisability to be assessed.
• Threshold analysis: A definition of the threshold applied in the analysis must be clearly stated and justified.
• Probabilistic sensitivity analysis: distributional assumptions should be justified and be consistent with any logical bounds on parameter values, and, where correlations are expected, joint distributions should be used.

Phase 2: Audit of cost-effectiveness work for NICE

An audit has been undertaken of the 15 most recent NICE multiple technology appraisal judgements and their related reports. This aspect of the work has reviewed and audited how sensitivity analysis has been undertaken by independent academic teams for NICE. The quality of the PSA has been judged using the criteria defined in Phase 1.

Practice in relation to univariate sensitivity analysis is highly variable, with considerable lack of clarity in relation to the methods used and the basis of the ranges employed. Further, the presentation of such analyses revealed room for improvement with the use of diagrams, such as tornado figures, very rare. In relation to PSA, there is a high level of variability in the form of distribution used for similar parameters, and the justification for such choices is rarely given. Virtually all analyses failed to consider correlations within the PSA, and this is an area of concern.

Phase 3: Review of NICE policy documents

This phase comprised a review of the policy and guidance documents issued by NICE relating to the topics selected in Phase 2. This review aimed to assess the policy impact of the sensitivity analysis and the PSA in particular.
This review found that uncertainty is considered explicitly in the process of arriving at a decision by the NICE Technology Appraisal Committee. The focus of attention is predominantly parameter uncertainty. The cited ranges of incremental cost-effectiveness ratios (ICERs) in the policy documents, and the most value in supporting decision-making, appear to have come from the deterministic analyses. This may, in part, reflect an issue of poor understanding of PSA or may reveal the value of deterministic approaches, especially in the search for subgroups. An association between high levels of uncertainty and negative decisions was suggested in the documents.

Phase 4: Interviews with NICE Committee members

Qualitative interview data from NICE Technology Appraisal Committee, collected as part of an earlier study, have been analysed. This work has assessed the value attached to the sensitivity analysis components of the economic analyses conducted for NICE (see Chapter 5).

The findings suggest considerable value in deterministic sensitivity analysis. Such analyses serve to highlight which model parameters are critical to driving a decision. Strong support was expressed for PSA, principally because it provides an indication of the parameter uncertainty around the ICER value. A concern expressed about PSA was that it can under-report the true level of uncertainty through the selection of a subset of parameters for inclusion in the analysis. Some Committee members expressed the view that where uncertainty is greater, the decision should tend towards a negative. Finally, the communication of sensitivity analysis results is less than optimal. A more detailed and clearer explanation of the sensitivity analysis is required.

Limitations

The focus for this work was on cost-effectiveness work undertaken by the independent academic teams for NICE, and so the cost-effectiveness work from industry, as part of the single technology assessment process, has not been reviewed. The review focused exclusively on documentary evidence – the models underlying the cost-effectiveness analyses were not available for scrutiny. The policy impact assessment was based only on documentary evidence again – observation of Committee discussions, and deliberations and/or interviews with Committee members around the specific topics might have revealed further insights on this issue. Finally, the interview data were taken from an earlier study in which the scope was broader than sensitivity analysis and uncertainty, and the data were collected in 2003/4, before the 2004 NICE Guide to the methods of technology appraisal was published.

Recommendations for practice and policy

In seeking to address parameter uncertainty, both deterministic and probabilistic sensitivity analyses should be used. For methodological and structural uncertainties, repeated analyses should be run using different models in which uncertainties regarding model structure exist or different methods in which there are uncertainties regarding methods.

In terms of the process of conducting and implementing sensitivity analyses, good practice would involve a clear and full justification of the choice of included variables, along with a clear explanation of the information source used to specify the ranges. The use of threshold analysis is to be supported, especially where the value of a particular parameter is indeterminate, but there is a need to provide a clear rationale for, and definition of, the threshold applied.

In relation to PSA, distributions should be placed around all important model parameters, and any excluded parameters must be justified. The distributional assumption for each variable should be justified and should relate to the nature of the variable. The distribution should be consistent with any logical bounds on parameter values given its nature (e.g. utility scores with an upper bound of 1). There might be value in clearer methodology guidelines on which distributions are appropriate for which parameters. Where correlation between variables is expected, joint distributions should be used and independence should not be assumed.

On the use of sensitivity analyses in policy-making, there may be benefits from an explicit recognition of the role of such analyses in supporting the search for subgroups. This issue of the possible association between level of uncertainty and the likelihood of a negative decision requires some further discussion. The data reported here suggest that when the level of uncertainty was high, the NICE Committee was likely to tend towards a
negative decision. Finally, the challenge of effective communication between analysts and policy-makers cannot be ignored. It is evident that some cost-effectiveness work, especially around the sensitivity analysis components, represents a challenge in making it accessible to those making decisions. This speaks to the training agenda for those sitting on such decision-making bodies, and to the importance of clear presentation of analyses by the academic community.

**Publication**

How to obtain copies of this and other HTA programme reports

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:
– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:
HTA Despatch
Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd
Tel: 02392 492 000
4 Oakwood Business Centre
Fax: 02392 478 555
Downley, HAVANT PO9 2NP, UK
Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
NIHR Health Technology Assessment programme

The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 07/56/01. The protocol was agreed in May 2007. The assessment report began editorial review in November 2008 and was accepted for publication in November 2008. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Aileen Clarke, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein